GV is set to exit customer data management platform Segment in an all-share deal that more than doubles its valuation from 18 months ago.

GV-backed cancer drug developer Kronos Bio floated above its range in an upsized offering and saw its shares soar in price post-IPO.

Merck Group, Bristol Myers-Squibb and Novo-backed cancer drug developer Galecto has filed to go public weeks after it last funding round.

Novo remains the largest shareholder in the endocrine disorder drug developer, which went public in an upsized offering.

Relx and Telus-backed TigerConnect has now raised $149m in equity and debt financing for its healthcare messaging and collaboration platform.

Cambrian Biopharma co-led a $28.5m round for cancer immunotherapy developer Sensei Biotherapeutics with venture capital firm H&S Ventures.

John Doherty, a GCV Powerlist award winner, becomes CFO as Walter Delph heads business.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Medical transcription technology provider Abridge has emerged from stealth with seed and series A funding.